Dept. Pharmacy and Pharmaceutical Technology and Center for Research in Molecular Medicine and Chronic Diseases (CIMUS), Campus Vida, Universidad de Santiago de Compostela, Spain.
J Control Release. 2012 Jul 20;161(2):496-504. doi: 10.1016/j.jconrel.2012.03.017. Epub 2012 Mar 23.
Chitosan-based nanocarriers have become one of the most intensively studied transmucosal nanometric drug delivery platforms. This is due to a number of factors, including their simple and mild preparation technique as well as their capacity to associate macromolecules and facilitate their transport across mucosal barriers. In this review, we first describe our contribution to the origin of chitosan nanocarriers in the mid 90s, and summarize the early work that has impacted the development of this delivery technology. Secondly, we present our perspective regarding the potential of chitosan nanocarriers for some relevant applications: (i) vaccination, (ii) transmucosal protein delivery and (iii) gene therapy. Finally, we offer our perspective on the plausible advances in this area in the near future.
基于壳聚糖的纳米载体已成为最受关注的黏膜给药纳米药物传递平台之一。这是由于许多因素，包括其简单温和的制备技术，以及其与大分子结合并促进其穿过黏膜屏障的能力。在这篇综述中，我们首先描述了我们在 90 年代中期对壳聚糖纳米载体起源的贡献，并总结了对该递药技术发展有影响的早期工作。其次，我们介绍了我们对壳聚糖纳米载体在一些相关应用中的潜力的看法：（i）疫苗接种，（ii）黏膜蛋白传递和（iii）基因治疗。最后，我们对该领域在不久的将来可能取得的进展提出了看法。
